DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
PYROPHOSPHORIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PYROPHOSPHORIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
4E862E7GRQ
Molecule Type:
Small molecule
Molecular Formula:
H4O7P2
Molecular Weight:
177.97
AlogP:
-0.81
PSA:
124.29
HBD:
4.0
HBA:
#RotB:
2.0
Source:
ANTIMONY
2
Small molecule
Investigational
Unknown
Unknown
Leishmaniasis, Cutaneous
Unknown
ANTIMONY
×
Maximum Phase:
2
First Approval:
None
UNII:
9IT35J3UV3
Molecule Type:
Small molecule
Molecular Formula:
Sb
Molecular Weight:
121.76
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
MITOQUINONE CATION
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MITOQUINONE CATION
×
Maximum Phase:
2
First Approval:
None
UNII:
47BYS17IY0
Molecule Type:
Small molecule
Molecular Formula:
C37H44O4P+
Molecular Weight:
583.73
AlogP:
7.46
PSA:
52.6
HBD:
0.0
HBA:
#RotB:
16.0
Source:
BMS-986253
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BMS-986253
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROBALZOTAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Serotonin 1a (5-HT1a) receptor antagonist
ROBALZOTAN
×
Maximum Phase:
2
First Approval:
None
UNII:
I18M56OGME
Molecule Type:
Small molecule
Molecular Formula:
C18H23FN2O2
Molecular Weight:
318.39
AlogP:
2.64
PSA:
55.56
HBD:
1.0
HBA:
#RotB:
4.0
Source:
PX-102
2
Small molecule
Investigational
Unknown
Unknown
Non-alcoholic Fatty Liver Disease
Bile acid receptor FXR agonist
PX-102
×
Maximum Phase:
2
First Approval:
None
UNII:
378SU5NO8S
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-223131
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Calcium-activated potassium channel subunit alpha-1 activator
BMS-223131
×
Maximum Phase:
2
First Approval:
None
UNII:
889F719S7K
Molecule Type:
Small molecule
Molecular Formula:
C18H13ClF3NO3
Molecular Weight:
383.75
AlogP:
4.11
PSA:
73.32
HBD:
3.0
HBA:
#RotB:
3.0
Source:
ORVEPITANT
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major; Stress Disorders, Post-Traumatic
Neurokinin 1 receptor antagonist
ORVEPITANT
×
Maximum Phase:
2
First Approval:
None
UNII:
IIU6V0W3JD
Molecule Type:
Small molecule
Molecular Formula:
C31H35F7N4O2
Molecular Weight:
628.63
AlogP:
6.8
PSA:
47.1
HBD:
0.0
HBA:
#RotB:
4.0
Source:
D-ASPARTATE
2
Small molecule
Investigational
Unknown
Unknown
Brain Injuries; Multiple Sclerosis, Relapsing-Remitting
Unknown
D-ASPARTATE
×
Maximum Phase:
2
First Approval:
None
UNII:
4SR0Q8YD1X
Molecule Type:
Small molecule
Molecular Formula:
C4H7NO4
Molecular Weight:
133.1
AlogP:
-1.13
PSA:
100.62
HBD:
3.0
HBA:
#RotB:
3.0
Source:
BORAGE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
BORAGE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AB122
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
AB122
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BAFETINIB
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Prostatic Neoplasms, Castration-Resistant
Tyrosine-protein kinase ABL inhibitor
BAFETINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
NVW4Z03I9B
Molecule Type:
Small molecule
Molecular Formula:
C30H31F3N8O
Molecular Weight:
576.63
AlogP:
5.39
PSA:
99.17
HBD:
2.0
HBA:
#RotB:
8.0
Source:
THK-5351
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
THK-5351
×
Maximum Phase:
2
First Approval:
None
UNII:
JE3F6WUN31
Molecule Type:
Small molecule
Molecular Formula:
C18H18FN3O2
Molecular Weight:
327.36
AlogP:
3.05
PSA:
67.27
HBD:
2.0
HBA:
#RotB:
6.0
Source:
DOLASTATIN-10
2
Small molecule
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Gallbladder Neoplasms; Kidney Neoplasms; Leukemia; Lymphoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma
Tubulin inhibitor
DOLASTATIN-10
×
Maximum Phase:
2
First Approval:
None
UNII:
EI946JT51X
Molecule Type:
Small molecule
Molecular Formula:
C42H68N6O6S
Molecular Weight:
785.11
AlogP:
5.19
PSA:
133.41
HBD:
2.0
HBA:
#RotB:
21.0
Source:
TRETAZICAR
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular
Unknown
TRETAZICAR
×
Maximum Phase:
2
First Approval:
None
UNII:
7865D5D01M
Molecule Type:
Small molecule
Molecular Formula:
C9H8N4O5
Molecular Weight:
252.19
AlogP:
0.42
PSA:
132.38
HBD:
1.0
HBA:
#RotB:
4.0
Source:
CE-224535
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Osteoarthritis
P2X purinoceptor 7 antagonist
CE-224535
×
Maximum Phase:
2
First Approval:
None
UNII:
T8B02RAU3C
Molecule Type:
Small molecule
Molecular Formula:
C22H29ClN4O6
Molecular Weight:
480.95
AlogP:
0.87
PSA:
135.68
HBD:
3.0
HBA:
#RotB:
8.0
Source:
BEPIROVIRSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Hepatitis B, Chronic
mRNA antisense inhibitor
BEPIROVIRSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TEW-7197
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
TEW-7197
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SRL-172
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
SRL-172
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ETILEVODOPA
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Dopamine D3 receptor agonist
ETILEVODOPA
×
Maximum Phase:
2
First Approval:
None
UNII:
895X917GYE
Molecule Type:
Small molecule
Molecular Formula:
C11H15NO4
Molecular Weight:
225.24
AlogP:
0.53
PSA:
92.78
HBD:
3.0
HBA:
#RotB:
4.0
Source:
RONTALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic
Interferon alpha inhibitor
RONTALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
LDO2FIQ61I
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SIMTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Cholangitis, Sclerosing; Colorectal Neoplasms; Idiopathic Pulmonary Fibrosis; Liver Cirrhosis; Pancreatic Neoplasms; Primary Myelofibrosis
Lysyl oxidase homolog 2 inhibitor
SIMTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
11Z5AIU653
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AFQ056
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
AFQ056
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OBEXELIMAB
2
Antibody
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic
B-lymphocyte antigen CD19 inhibitor
OBEXELIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
RM16A4BA8R
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VESTIPITANT
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major; Phobia, Social; Postoperative Nausea and Vomiting; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Tinnitus
Unknown
VESTIPITANT
×
Maximum Phase:
2
First Approval:
None
UNII:
S052TOI9BI
Molecule Type:
Small molecule
Molecular Formula:
C23H24F7N3O
Molecular Weight:
491.45
AlogP:
5.93
PSA:
35.58
HBD:
1.0
HBA:
#RotB:
3.0
Source:
ODIPARCIL
2
Small molecule
Investigational
Unknown
Unknown
Atrial Fibrillation; Mucopolysaccharidosis VI
Glycosaminoglycans modulator
ODIPARCIL
×
Maximum Phase:
2
First Approval:
None
UNII:
FIK1414ZI8
Molecule Type:
Small molecule
Molecular Formula:
C15H16O6S
Molecular Weight:
324.35
AlogP:
0.64
PSA:
100.13
HBD:
3.0
HBA:
#RotB:
2.0
Source:
TELATINIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Stomach Neoplasms
Platelet-derived growth factor receptor beta inhibitor
TELATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
18P7197Q7J
Molecule Type:
Small molecule
Molecular Formula:
C20H16ClN5O3
Molecular Weight:
409.83
AlogP:
3.95
PSA:
102.17
HBD:
2.0
HBA:
#RotB:
6.0
Source:
TALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Ig epsilon chain C region inhibitor
TALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
9591BL735Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IDEC-159
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Tumor-associated antigen 72 inhibitor
IDEC-159
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CNV2197944
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies; Neuralgia, Postherpetic
Voltage-gated N-type calcium channel alpha-1B subunit blocker
CNV2197944
×
Maximum Phase:
2
First Approval:
None
UNII:
SSB9S6N20R
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALOVUDINE
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Unknown
ALOVUDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
PG53R0DWDQ
Molecule Type:
Small molecule
Molecular Formula:
C10H13FN2O4
Molecular Weight:
244.22
AlogP:
-0.54
PSA:
84.32
HBD:
2.0
HBA:
#RotB:
2.0
Source:
DAVUNETIDE
2
Protein
Investigational
Unknown
Unknown
Cognitive Dysfunction; Schizophrenia; Supranuclear Palsy, Progressive
Tubulin stabiliser
DAVUNETIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
GF00K3IIWE
Molecule Type:
Protein
Molecular Formula:
C36H60N10O12
Molecular Weight:
824.93
AlogP:
-4.34
PSA:
355.85
HBD:
10.0
HBA:
#RotB:
22.0
Source:
M1095
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
M1095
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
2-HYDROXYOLEIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Glioma; Glioblastoma
Unknown
2-HYDROXYOLEIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
OSV3KVO1BT
Molecule Type:
Small molecule
Molecular Formula:
C18H34O3
Molecular Weight:
298.47
AlogP:
5.08
PSA:
57.53
HBD:
2.0
HBA:
#RotB:
15.0
Source:
MERICITABINE
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
MERICITABINE
×
Maximum Phase:
2
First Approval:
None
UNII:
TA63JX8X52
Molecule Type:
Small molecule
Molecular Formula:
C18H26FN3O6
Molecular Weight:
399.42
AlogP:
1.22
PSA:
122.74
HBD:
1.0
HBA:
#RotB:
6.0
Source:
1
2
…
170
171
172
173
174
175
176
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA